Clinical Trials Browser

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

NCT05460000 2026-02-12

N-Plus

Phase 2 Recruiting

640 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT06023862 2025-06-15

DOVE

Phase 2 Recruiting

198 enrolled

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT03241745 2024-12-27

A Study of Nivolumab in Selected Uterine Cancer Patients

Phase 2 Completed

35 enrolled 8 charts

GynecologicSarcoma

Carcinosarcoma, Leiomyosarcoma, Uterine Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT04227522 2024-11-15

MAMOC

Phase 3 Completed

42 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT02129036 2019-08-09

OCCA

Completed

5 enrolled

Gynecologic

Ovarian Cysts, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT01824615 2018-07-18

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

Phase 2 Completed

30 enrolled

Gynecologic

Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT00231829 2012-04-24

A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers

Phase 2 Terminated

23 enrolled

Gynecologic

Uterine Neoplasms, Adenocarcinoma, Clear Cell

Clinical Trials

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

N-Plus

DOVE

A Study of Nivolumab in Selected Uterine Cancer Patients

MAMOC

OCCA

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers